Rising Tide VC ’s Post

Congratulations, Aspect Biosystems, for securing a $73 million investment from the Governments of Canada and British Columbia. The funding will support a $200 million, multi-year project to advance Aspect’s unique clinical biomanufacturing capabilities and pipeline of bioprinted tissue therapeutics. Bioprinted tissue therapy is a cutting-edge approach to creating functional human tissue using 3D bioprinting technology. This innovative therapy involves the precise layer-by-layer deposition of biocompatible materials, cells, and bioactive factors to construct living tissue structures. These bioprinted tissues can be designed to mimic the complex architecture and cellular composition of human tissues, with the ultimate goal of replacing, repairing, or supplementing biological functions within the body. This approach holds great promise for developing advanced treatments for various diseases and has the potential to revolutionize the field of regenerative medicine. Check out the full announcement at www.aspectbiosystems.com. #Biotech #HealthcareInnovation #Investment #CanadaBioTech

#fundingalert 💼Company: Neurenati Therapeutics 💰Funding: $1.38Million ⚡Round: New Round 👥Investors: Quebec government Innovative biotechnology business Neurenati Therapeutics is creating a novel treatment for Hirschsprung’s illness. The rare illness specialist Nicolas Pilon and the neuro-gastroenterology specialist Rodolphe Soret have joined forces to create a novel treatment for Hirschsprung’s disease. The biotech business Neurenati Therapeutics, led by CEO and President Maxime Ranger, is committed to creating treatments for uncommon illnesses. The first piece of technology focuses on Hirschsprung disease (HSCR), a potentially fatal gastrointestinal (GI) birth abnormality marked by nerve loss in certain areas of the lower gastrointestinal tract. Nicolas Pilon, Rodolphe Soret, Maxime Ranger Read more - https://lnkd.in/g4FVCtZK To share your startup story write us on - contact@startuprise.io #NeurenatiTherapeutics #biotech #Innovative #biotechnology #biotechstartup #funding #fundingnews #startupnews #news #startuprise

A world where treatments exist for many serious and currently deemed incurable illnesses and diseases, including heart disease, cancer and Alzheimer’s, could one day be a reality thanks to improved oligonucleotide therapeutics production💡 With the establishment of the Oligonucleotide Manufacturing Innovation Centre of Excellence, led by CPI, Scotland plans to propel oligo production forward by leveraging innovative manufacturing technologies. This groundbreaking initiative, awarded a multi-million-pound grant in the UK Government's 2023 Autumn Statement, aims to address critical issues surrounding the manufacturing and sustainability of oligonucleotides (oligos). “We recognise that there is not a magic bullet to making them more sustainable, cheaper and scalable. You need to have a portfolio of options to pick the right solution for the right molecules.” Barrie Cassey, Medicines Manufacturing Technology Lead at CPI. Heralded as revolutionary therapeutics, by investing in oligos manufacturing and working in close partnership with involved parties, treatments for some of the most serious diseases on the planet, could be transformed in Scotland and may even one day provide a cure 🌎💚 Discover how Scotland is focusing on sustainability in healthcare and how it's poised as the global hub for oligo production 👉 #ScotlandIsNow #Manufacturing #Healthcare

The life sciences sector continues to drive innovation, with notable achievements pushing the boundaries of healthcare solutions. From leadership appointments to clinical breakthroughs, these recent milestones are shaping the future of patient care and medical technology: Benitec Biopharma Inc. presented positive data from two subjects treated with low-dose BB-301 in a Phase 1b/2a study at the 29th Annual Congress of the World Muscle Society. CuraSen Therapeutics, Inc. Therapeutics appointed Kathleen Sereda Glaub as its new Chief Executive Officer. MEDIC Life Sciences, led by Kyuho Han, secured $5M in strategic investments from LG and Hanmi to drive the adoption of its innovative cancer biomarker discovery technology. Adicet Bio, Inc received FDA clearance of an IND amendment to evaluate ADI-001 in Idiopathic Inflammatory Myopathy and Stiff Person Syndrome. DNA Script appointed Marc Montserrat as CEO to drive long-term commercial growth for its groundbreaking enzymatic DNA synthesis platform. As the life sciences industry continues to evolve, these accomplishments reflect the transformative work driving progress in biotech and healthcare. Stay tuned for more exciting updates! #LifeScience #Biotech #HealthTech #Innovation #Healthcare #ClinicalTrials #FDAApproval #Pharma #BiotechNews #DrugDevelopment #MedTech #Leadership #CancerResearch #DNASynthesis #RareDiseases #CEO

Today, Novo Nordisk announced an investment in Tanai Therapeutics; a startup company looking to discover an oral therapeutic targeting a novel mechanism in obesity that plays a crucial role in energy expenditure. This target offers a promising new approach to obesity treatment and has been shown to selectively promote fat loss through increased energy expenditure, while preserving muscle mass. This is the first investment in a newly launched Novo Nordisk investment programme called Science2Medicine iNNvest, which gives us the capability to invest in promising early stage biotechs within the cardiometabolic space. Even though obesity is now a treatable disease with medications addressing hunger and satiety, regulation of energy expenditure is an important piece of the puzzle – and it is still missing, and I am so pleased that we can now accelerate the research within energy expenditure. I am looking forward to seeing this investment accelerating science and drug development for the benefit of patients. https://lnkd.in/dcHFBMkz #Science2Medicine #biotechs #cardiometabolic #venturecapital 

Europe Exosome Research Market size was valued at US$ 40.24 Mn. in 2023 and the total revenue is expected to grow at 11.4% through 2024 to 2030, reaching nearly US$ 85.69 Mn. by 2030. Request For a Sample Report : https://lnkd.in/d8siV6rz Uncover key developments, emerging trends, and the potential impact of exosomes on diagnostics and therapeutics. Equip your business with the latest insights and stay at the forefront of this cutting-edge scientific frontier. #ExosomeResearch #MarketReport #EuropeMarket #Biotech #HealthcareInnovation #Diagnostics #Therapeutics #MarketInsights #ScientificAdvancements #ResearchAndDevelopment

ANXA5, or Annexin A5, is a protein with multifaceted capabilities, ranging from its role in cell membrane organization to its involvement in the regulation of apoptosis (programmed cell death). This remarkable protein has garnered immense attention within the scientific community for its potential applications in various fields, including cancer research, cardiovascular health, and reproductive medicine.   Top Companies:   Bio-Rad Laboratories Thermo Fisher Scientific R&D Systems LSBio | LifeSpan BioSciences, Inc. GeneTex, Inc. Atlas Antibodies Abbexa BioLegend Aviva Systems Biology Biorbyt EpigenTek Novus Biologicals LLC   Growth Report: https://bit.ly/4aup1KW   #annexina5 #biotechnology #pharmaceutical #drugdiscovery #vasculardisease #inflammation #healthcare #anxv #phospholipidbindingproteins #cellsignaling #drugdevelopment #clinicaltrials #investors #researchers #pharmaceuticalcompanies #healthcare #startup #marketgrowth #metastatinsight

𝐁𝐢𝐨𝐀𝐫𝐜𝐭𝐢𝐜 𝐚𝐧𝐝 𝐄𝐢𝐬𝐚𝐢 𝐂𝐨𝐥𝐥𝐚𝐛𝐨𝐫𝐚𝐭𝐞 𝐨𝐧 𝐍𝐞𝐱𝐭-𝐆𝐞𝐧 𝐀𝐥𝐳𝐡𝐞𝐢𝐦𝐞𝐫'𝐬 𝐓𝐫𝐞𝐚𝐭𝐦𝐞𝐧𝐭 BioArctic AB (Nasdaq Stockholm: BIOA B) BioArctic announced a research evaluation agreement with Eisai Co., Ltd. Eisai Co., Ltd., for BAN2802, combining BioArctic's BrainTransporter™ technology with an undisclosed Alzheimer drug candidate. Eisai Eisai Co., Ltd. will evaluate data to potentially license BAN2802 for Alzheimer's treatment. The collaboration builds on a longstanding partnership since 2005, resulting in Leqembi® (lecanemab), the first approved drug shown to slow early Alzheimer's progression. The joint knowledge will fuel the evaluation of the next generation Alzheimer's treatment. Costs will be shared. Gunilla Osswald Gunilla Osswald, CEO at BioArctic, highlighted the potential of the BrainTransporter technology to improve various projects. The technology actively transports biologics across the blood-brain barrier, enhancing treatment efficacy while reducing patient and societal burdens. #AlzheimersResearch #BioArctic #Eisai #BrainHealth #MedicalInnovation #Collaboration #DrugDevelopment #Healthcare #BrainTransporter #ClinicalTrials

Business Development Update: Our CTO, Dr. Vivek K. Vishnudas, recently presented our E2-centric targeted protein degradation platform at the 15th Annual Drug Discovery Innovation Forum in Berlin. The positive response from industry innovation leaders highlights the potential of this technology to open new pathways for molecular glues and heterobifunctional chimeras. A core strength of our platform is its focus on selectivity and specificity, utilizing a 1,000 Ro3 proprietary compound library to optimize ligands. By leveraging the E2 enzyme, which is more highly expressed than E3, we avoid using CRBN or other thalidomide-based ligands. This enhances safety, efficacy, and improves manufacturing efficiency by reducing the complexity of production processes. This innovation is set to unlock new therapeutic possibilities, particularly in oncology and neurology, as we explore strategic partnerships to advance clinical development. We look forward to collaborating with partners committed to transforming healthcare through responsible and efficient drug discovery. #BusinessDevelopment #BiotechInnovation #MolecularGlues #HeterobifunctionalChimeras #TargetedProteinDegradation #SelectiveSpecific #ManufacturingExcellence #Collaborations

New Hopes For Gout Patients Worldwide – AR882! Arthrosi Therapeutics, Inc., an HKSTP Venture Fund-backed biotech company, has received FDA Fast Track Designation for AR882 in tophaceous gout - a potentially best-in-class treatment for gout. Clinical trials have shown that AR882 can significantly reduce serum urate levels, flares and tophi in patients with gout compared to existing treatments. With more than 50 million people globally suffering from this painful form of arthritis, AR882's highly potent and selective next-generation URAT1 inhibitor is a sign of hope for many. We're proud to support Hong Kong’s biomedical breakthroughs, cultivating solutions like this that improve lives worldwide. Struggling to translate quality research into good business? We can help: stp.hk/4efiIxd #HKSTP #PropellingSuccess #BioTech